Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06190821
Other study ID # 8695
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date July 20, 2022
Est. completion date February 20, 2025

Study information

Verified date December 2023
Source University Hospital, Strasbourg, France
Contact Julien GARNON, MD
Phone 33 3.69.55.03.04
Email julien.garnon@chru-strasbourg.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Percutaneous treatment of liver lesions adjacent to the duodenum exposes the duodenum to the risk of thermal injury, limiting removal and oncologic outcome. In this study the investigators investigate the feasibility of hepato duodenal ligament dissection in the percutaneous treatment of liver lesions adjacent to the duodenum.


Recruitment information / eligibility

Status Recruiting
Enrollment 13
Est. completion date February 20, 2025
Est. primary completion date February 2025
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria: - Major subject (=18 years of age) - Subject who underwent percutaneous ablation of primary or secondary liver lesions at HUS that required per-procedure hepatoduodenal ligament hydrodissection in the interventional imaging department of the New Civil Hospital from January 2019 to July 2022. - Subject who has not expressed opposition to the reuse of their data for the purpose of this research. Exclusion Criteria: - Opposition to the reuse of his/her data for the purpose of scientific research.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France Service Imagerie interventionnelle oncologique et viscérale - CHU de Strasbourg - France Strasbourg

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Retrospective description of the hepatoduodenal ligament dissection in the percutaneous treatment of liver lesions adjacent to the duodenum This study is retrospective Files analysed retrospectively from January 01, 2019 to July 31, 2022 will be examined
See also
  Status Clinical Trial Phase
Active, not recruiting NCT00852228 - Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy Phase 2